Enterprise Technology Center

Wanhe Enterprise Technology ( ETC ) led by the Chief Scientist, Professor Umezawa, was officially opened on 08 April 2017. It has 41 researchers and technicians and owns over 30 patents (including 15 invention patents). With a laboratory area of 2400 square meters, the center is equipped with adequate sophisticated instruments such as the high performance liquid chromatography, gas chromatography, atomic absorption photometer, automatic dissolution instrument, laser particle size analyser, ultr-fine air grinder, multi-purpose fluidized bed, quick mixing granulator to meet its R&D needs.


The center’s core strenghs include the domestic leading technologies of delayed-release pellet, orally disintegrating tablet and multi-layer dropping pill. The innovative drug “DHMEQ” under development is an anti-cancer & anti-inflammatory small molecule targeting drug with a completely new mechanism, which can offer new ideas for the treatment of atopic dermatitis and hopefully benefit the patients suffering from atopic dermatitis worldwide.


Besides the development of innovative drugs, the center is also putting effort on the development of functional food, mapping out strategies in the fields of gut health, sports nutrition, metabolism with premium probiotic&prebiotic products, sports nutrition products, weight management products and so on.


The center has been working in collaboration with universities at home and abroad such as Keio University, Aichi Mdedical University, Shenyang Pharmaceutical University, Shenzhen University, Nantong University, Beijing Institute Of Graphic Communication and established the Postgraduate Workstation and Practice Base.



Contact Us | Site Map

ICP Register No:Yue ICP 13048506 © 2007-2023 Wanhe Pharmaceutical., Ltd.      Powered by szweb